Amyotrophic Lateral Sclerosis and Frontotemporal Dementia: A Disease Spectrum

Version imprimable
February 19, 2018
Janice Robertson

On February 23th, 2018, the CRCHUM Conferences invites Janice Robertson, researcher at the Tanz Centre for Research in Neurodegenerative Diseases. The conference will discuss the clinical, genetic and neuropathological overlap between Amyotrophic lateral sclerosis and frontotemporal dementia.


Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease, is an adult-onset neurodegenerative disease characterized by the loss of motor neurons from the brain and spinal cord causing a progressive paralysis and death due to respiratory failure typically within 3-5 years from diagnosis. In recent years it has been recognized that approximately 50% of ALS patients develop cognitive impairment, and 10-15% fulfil the diagnostic criteria of frontotemporal dementia (FTD), the second most common cause of dementia in those under the age of 65. ALS and FTD are now considered the two extremes of a disease spectrum. The talk will cover the clinical, genetic and neuropathological overlap between ALS and FTD, focusing on GGGGCC repeat expansions in C9orf72, which is the most common genetic cause of ALS/FTD.

This conference will be presented in English.

Friday, February 23th, 2018, at noon
Auditorium of the CRCHUM, R05.210 and R05.220
900 Saint-Denis Street, 5th floor 
Montreal (Quebec)  H2X 0A9

Marc Ouellette, Ph.D., FRSC, FCAHS
Scientific Director, Institute of Infection and Immunity - CIHR
Canada Research Chair in Antimicrobial Resistance 
Full Professor, Département de microbiologie, infectiologie et immunologie, Faculté de médecine, Université Laval


About CRCHUM Conferences

The CRCHUM Conferences are free weekly meetings featuring renowned scientific speakers from various disciplines. These conferences are accredited by the Royal College of Physicians and Surgeons of Canada as continuing professional development activities. The CRCHUM conferences are made possible thanks to the financial support of our partners: AstraZeneca, Banque Nationale, Biron, Charles River, GSK Canada, Lilly, Médicaments novateurs Canada, Merck, Pfizer, Québecor, Roche & Servier.

About our scientific activities

Schedule of scientific activities at the CRCHUM